Fannie Mae Tackles Mortgage Fraud Amidst Employee Terminations

Published 2 days agoPLTR

Fannie Mae Tackles Mortgage Fraud Amidst Employee Terminations

As of May 28, 2025, there is no public record indicating a collaboration between Palantir and Fannie Mae to use AI in mortgage fraud detection. Nevertheless, both entities have been proactive in combating mortgage fraud through various efforts. Fannie Mae recently terminated more than 100 employees for unethical conduct linked to fraud and has faced significant financial losses due to fraudulent activities. In November 2024, the company reported a $752 million credit loss provision attributed to fraud in multifamily lending transactions, according to a report by Bloomberg Law.

To enhance its detection capabilities, Fannie Mae has integrated machine learning models into its credit risk assessment framework. This move aims to bolster the company's defense against fraudulent activities. Palantir, known for its robust data analysis capabilities, has previously partnered with Better HoldCo in 2022 to develop a platform to improve data-driven decisions in the mortgage industry, as reported by Inman.

Despite these efforts, there remains no evidence of a direct collaboration between Palantir and Fannie Mae specifically focused on mortgage fraud detection. Both organizations continue to independently address the challenges posed by mortgage fraud through their respective technologies and strategies.

Share this article

Twitter Facebook LinkedIn

Recent Articles

Tesla's Stock Soars 22% in May Amid Key Developments

Tesla's Stock Soars 22% in May Amid Key Developments

13 minutes agoTSLA

Tesla's stock witnessed a remarkable surge in May 2025, closing the month with an impressive 22% gain. This uptick coincided with several pivotal events, starting with Elon Musk's announcement to scale back his involvement with the Department of Government Efficiency. This shift was perceived as a signal of his renewed focus on Tesla's strategic goals, as reported by Time. Further fueling investor enthusiasm was Tesla's earnings report, which exceeded expectations and contributed significantly to the stock's performance. NBCDFW highlighted this news, noting the 22% rise in stock value post-announcement. Additionally, regulatory changes provided a boost as the U.S. Department of Transportation eased constraints for autonomous vehicles, aligning with Tesla's ambitions in autonomous driving. Adding to the positive momentum, Elon Musk revealed plans to introduce a new, more affordable electric vehicle model aimed at dominating the mass market. Named the 'Model 2,' this initiative aims to broaden Tesla's consumer base and enhance its competitive edge. These combined factors have contributed to the buoyant outlook for Tesla, leading to its notable stock performance in May 2025.

Entera Bio Files $100 Million Shelf Registration with SEC

Entera Bio Files $100 Million Shelf Registration with SEC

28 minutes agoENTX

Entera Bio Ltd. has recently filed a $100 million mixed securities shelf registration statement with the U.S. Securities and Exchange Commission (SEC). This filing allows the company to offer and sell various securities, including ordinary and preferred shares, debt securities, warrants, and units, providing the flexibility to raise capital as needed over time. In a related development, Entera Bio completed a private placement in December 2023, where it issued approximately 7.9 million units at $0.835 per unit. This effort raised about $6.6 million, and as of June 30, 2024, the company reported having $9.1 million in cash and cash equivalents. Reuters reported that this capital is expected to support their operations into the third quarter of 2025, covering a range of expenses such as regulatory and research costs. The newly filed registration aligns with Entera Bio's broader strategic goals. The company intends to use potential future offering proceeds for general working capital, clinical trials, and regulatory activities, ensuring its financial stability and supporting ongoing corporate initiatives. This move also highlights the company's commitment to regulatory compliance and transparency in its financial operations.

Cheniere Energy Initiates Maintenance at Sabine Pass LNG Plant

Cheniere Energy Initiates Maintenance at Sabine Pass LNG Plant

43 minutes agoLNG

Cheniere Energy has started its scheduled annual maintenance at the Sabine Pass LNG facility in Texas, the largest in the United States. This significant plant, with a capacity of 30 million metric tonnes per year, will see maintenance activities carried out from June 2 to June 23, 2025, a move confirmed by the company. This maintenance period is anticipated to temporarily reduce the U.S. LNG output, an impact that could also affect global LNG prices, Reuters reported. As part of the maintenance, gas flows to the Sabine Pass plant are expected to fall from 3.9 billion cubic feet per day (bcfd) to 3.7 bcfd, the lowest level in 11 months. Additionally, at Cheniere's Corpus Christi plant, feedgas levels are forecasted to drop from 2.1 bcfd to 1.6 bcfd during this time. Energy traders are expecting overall U.S. LNG feedgas volumes in June to remain below April's record highs due to the scheduled maintenance activities. Cheniere undertakes such upkeep regularly to ensure the efficient operation of their facilities, maintaining the reliability and safety of their LNG production capabilities.

CytomX Hits 52-Week High Amid Strong Financial Performance

CytomX Hits 52-Week High Amid Strong Financial Performance

58 minutes agoCTMX

CytomX Therapeutics Inc. has reached a 52-week high, with its stock climbing to $2.66 per share. As of May 30, 2025, the shares closed at $2.55 after an intraday high of $2.65. This positive stock performance marks a notable turnaround for the company and reflects growing investor confidence. In the fourth quarter of 2024, CytomX reported impressive total revenue of $138.1 million, significantly outpacing forecasts of $12.24 million. This financial success is largely due to their fruitful partnerships with industry giants such as Bristol Myers Squibb, Moderna, Astellas, and Regeneron. Investing.com highlighted these collaborations as key drivers behind the company's robust financial results. CytomX is also making strides in its clinical pipeline. The company is advancing programs like CX-2051 and CX-8001, with initial Phase 1 data for CX-2051 expected in the first half of 2025. Plans are also underway to start a combination study of CX-8001 with KEYTRUDA in the latter half of the year. Analysts, as reported by defenseworld.net, have given CytomX a 'Moderate Buy' rating, with an average price target of $5.77, indicating continued interest in the company's potential growth.